250 related articles for article (PubMed ID: 11788011)
1. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly.
Cozzi R; Barausse M; Sberna M; Lodrini A; Franzini A; Lasio G; Attanasio R
Pituitary; 2000 Dec; 3(4):231-8. PubMed ID: 11788011
[TBL] [Abstract][Full Text] [Related]
2. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly.
Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R
J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759
[TBL] [Abstract][Full Text] [Related]
3. Results of a two-year treatment with slow release lanreotide in acromegaly.
Cannavò S; Squadrito S; Curtò L; Almoto B; Vieni A; Trimarchi F
Horm Metab Res; 2000 Jun; 32(6):224-9. PubMed ID: 10898551
[TBL] [Abstract][Full Text] [Related]
4. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide.
Attanasio R; Barausse M; Cozzi R
J Endocrinol Invest; 2001 Apr; 24(4):209-16. PubMed ID: 11383906
[TBL] [Abstract][Full Text] [Related]
5. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma.
Cannavò S; Squadrito S; Curtò L; Almoto B; Trimarchi F
Horm Metab Res; 2001 Oct; 33(10):618-24. PubMed ID: 11607883
[TBL] [Abstract][Full Text] [Related]
7. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.
Chanson P; Leselbaum A; Blumberg J; Schaison G
Pituitary; 2000 May; 2(4):269-76. PubMed ID: 11081148
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
12. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly.
Chanson P; Borson-Chazot F; Kuhn JM; Blumberg J; Maisonobe P; Delemer B;
Clin Endocrinol (Oxf); 2008 Aug; 69(2):299-305. PubMed ID: 18248639
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
14. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
al-Maskari M; Gebbie J; Kendall-Taylor P
Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly.
Lombardi G; Minuto F; Tamburrano G; Ambrosio MR; Arnaldi G; Arosio M; Chiarini V; Cozzi R; Grottoli S; Mantero F; Bogazzi F; Terzolo M; Tita P; Boscani PF; Colao A
J Endocrinol Invest; 2009 Mar; 32(3):202-9. PubMed ID: 19542735
[TBL] [Abstract][Full Text] [Related]
16. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide.
Caron P; Morange-Ramos I; Cogne M; Jaquet P
J Clin Endocrinol Metab; 1997 Jan; 82(1):18-22. PubMed ID: 8989225
[TBL] [Abstract][Full Text] [Related]
17. Effect of gender and gonadal status on the long-term response to somatostatin analogue treatment in acromegaly.
Colao A; Pivonello R; Cappabianca P; Briganti F; Tortora F; Auriemma RS; De Martino MC; Marzullo P; Lombardi G
Clin Endocrinol (Oxf); 2005 Sep; 63(3):342-9. PubMed ID: 16117824
[TBL] [Abstract][Full Text] [Related]
18. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR.
Alexopoulou O; Abrams P; Verhelst J; Poppe K; Velkeniers B; Abs R; Maiter D
Eur J Endocrinol; 2004 Sep; 151(3):317-24. PubMed ID: 15362960
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
